{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:09:06Z","timestamp":1788196146061,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12936-018-2555-3","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T07:58:53Z","timestamp":1541491133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines"],"prefix":"10.1186","volume":"17","author":[{"given":"Jonathan","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Toovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"2555_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/cne.900910303","volume":"91","author":"I Schmidt","year":"1949","unstructured":"Schmidt I. Neurotoxicity of the 8-aminoquinolines; reactions of various experimental animals to\u00a0plasmocid. J Comp Neurol. 1949;91:337\u201367.","journal-title":"J Comp Neurol."},{"key":"2555_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00005072-194810000-00002","volume":"7","author":"IG Schmidt","year":"1948","unstructured":"Schmidt IG, Schmidt LH. Neurotoxicity of the 8-aminoquinolines I. Lesions in the central nervous system of Rhesus monkeys induced by administration of plasmocid. J Neuropathol Exp Neurol. 1948;7:368\u201398.","journal-title":"J Neuropathol Exp Neurol."},{"key":"2555_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005072-195107000-00001","volume":"10","author":"IG Schmidt","year":"1951","unstructured":"Schmidt IG, Schmidt LH. Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine and pamaquine on the central nervous system of the Rhesus monkey. J Neuropath Exp Neurol. 1951;10:231\u201356.","journal-title":"J Neuropath Exp Neurol"},{"key":"2555_CR4","volume-title":"Safety of 8-aminoquinoline antimalarial medicines","author":"J Recht","year":"2014","unstructured":"Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014."},{"key":"2555_CR5","unstructured":"US FDA approves Krintafel for the radical cure of Plasmodium vivax malaria. \n                    http:\/\/us.gsk.com\/en-us\/media\/press-releases\/2018\/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria\/\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR6","unstructured":"US Food and Drug Administration Approves ARAKODA\u2122 (tafenoquine) tablets for oral use. \n                    https:\/\/60degreespharma.com\/wp-content\/uploads\/2018\/08\/60P-PR-Release_TQ_Approval-8.21.18.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR7","first-page":"CD006491","volume":"10","author":"M Tickell-Painter","year":"2017","unstructured":"Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D. Mefloquine for preventing malaria during travel to endemic areas. Cochrane Database Syst Rev. 2017;10:CD006491.","journal-title":"Cochrane Database Syst Rev."},{"key":"2555_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1128\/AAC.50.3.1045-1053.2006","volume":"50","author":"GS Dow","year":"2006","unstructured":"Dow GS, Dow G, Bauman R, Caridha D, Cabezas M, Du F, et al. Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother. 2006;50:1045\u201353.","journal-title":"Antimicrob Agents Chemother"},{"key":"2555_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tmaid.2008.12.004","volume":"7","author":"S Toovey","year":"2009","unstructured":"Toovey S. Mefloquine neurotoxicity\u2014a literature review. Travel Med Infect Dis. 2009;7:2\u20136.","journal-title":"Travel Med Infect Dis."},{"key":"2555_CR10","unstructured":"US Food and Drug Administration. Prescribing information for ARAKODA\u2122. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210607lbl.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tmaid.2017.05.008","volume":"17","author":"A Novitt-Moreno","year":"2017","unstructured":"Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S. Tafenoquine for malaria prophylaxis in adults: an integrated safety analysis. Travel Med Infect Dis. 2017;17:19\u201327.","journal-title":"Travel Med Infect Dis."},{"key":"2555_CR12","unstructured":"Repatriation Medical Authority. Declaration Under 196b6. Commonwealth of Australia Government Gazette; 29 August 2017. \n                    www.rma.gov.au\/assets\/Other\/ff384f777c\/RMA-Declaration-chemically-acquired-brain-injury-caused-by-mefloquine-tafenoquine-or-primaquine-29-August-2017.pdf\n                    \n                   Accessed 22 June 2018."},{"key":"2555_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.tmaid.2017.05.006","volume":"17","author":"GS Dow","year":"2017","unstructured":"Dow GS, Brown T, Reid M, Smith B, Toovey S. Tafenoquine is not neurotoxic at following supertherapeutic dosing in rats. Travel Med Infect Dis. 2017;17:28\u201334.","journal-title":"Travel Med Infect Dis."},{"key":"2555_CR14","unstructured":"US Food and Drug Administration. 2018. NDA 210607: Tafenoquine for the prevention of malaria. Presentation slides for the FDA Antimicrobial Drugs Advisory Committee Meeting\u2014July 26, 2018. Available online at: \n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM615299.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Amal L, Harvey B. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.","journal-title":"BMC Psychiatry."},{"key":"2555_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0209-8","author":"S Glasner-Edwards","year":"2014","unstructured":"Glasner-Edwards S, Mooney L. Metamphetamine psychosis: epidemiology and management. CNS Drugs. 2014. \n                    https:\/\/doi.org\/10.1007\/s40263-014-0209-8\n                    \n                  .","journal-title":"CNS Drugs."},{"key":"2555_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1192\/bjp.172.1.23","volume":"172","author":"LV Kessing","year":"1998","unstructured":"Kessing LV, Anderson PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry. 1998;172:23\u20138.","journal-title":"Br J Psychiatry."},{"key":"2555_CR18","unstructured":"Degrees Pharmaceuticals LLC. 2018. NDA 210607: Arakoda\u2122 (Tafenoquine succinate) tablets for the prevention of malaria in adults. Briefing slides for the FDA Antimicrobial Drugs Advisory Committee Meeting\u2014July 26, 2018. \n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM615300.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR19","unstructured":"Degrees Pharmaceuticals LLC. 2018. NDA 210607: Arakoda\u2122 (Tafenoquine succinate) tablets for the prevention of malaria in adults. Briefing document for the FDA Antimicrobial Drugs Advisory Committee Meeting\u2014July 26, 2018. Available online at: \n                    https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM614202.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"issue":"Suppl 3","key":"2555_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4269\/ajtmh.1982.31.609","volume":"31","author":"LH Schmidt","year":"1982","unstructured":"Schmidt LH. Plasmodium cynomolgi infections in the Rhesus monkey. Am J Trop Med Hyg. 1982;31(Suppl 3):609\u201311.","journal-title":"Am J Trop Med Hyg"},{"key":"2555_CR21","volume-title":"Guidance for Industry: Estimating the maximum safe starting dose initial clinical trials in healthy adult volunteers","author":"CDER","year":"2005","unstructured":"CDER. Guidance for Industry: Estimating the maximum safe starting dose initial clinical trials in healthy adult volunteers. Washington: Department of Health & Human Services; 2005."},{"key":"2555_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/0003-4819-25-1-103","volume":"25","author":"M Hardgrove","year":"1946","unstructured":"Hardgrove M, Appelbaum IL. Plasmochin toxicity; analysis of 258 cases. Ann Intern Med. 1946;25:103\u201312.","journal-title":"Ann Intern Med"},{"key":"2555_CR23","first-page":"285","volume":"9","author":"JH Edgcomb","year":"1950","unstructured":"Edgcomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L, Jeffery GM, et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285\u201392.","journal-title":"J Natl Malar Soc."},{"issue":"Suppl 3","key":"2555_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.4269\/ajtmh.1982.31.666","volume":"31","author":"LH Schmidt","year":"1982","unstructured":"Schmidt LH, Fradkin R, Genther CS, Hughes HB. Delineation of the potentials of primaquine as a radical curative and prophylactic drug. Am J Trop Med Hyg. 1982;31(Suppl 3):666\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"2555_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00005072-197307000-00009","volume":"32","author":"JC Sipe","year":"1973","unstructured":"Sipe JC, Vick NA, Schulman S, Fernandez C. Plasmocid encephalopathy in the Rhesus monkey: a study of selective vulnerability. J Neuropathol Exp Neurol. 1973;32:446\u201357.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2555_CR26","unstructured":"Sanders K. 2018. Teach Me Anatomy. \n                    http:\/\/teachmeanatomy.info\/head\/cranial-nerves\/summary\/\n                    \n                  . Accessed 31 Aug 2018."},{"key":"2555_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","volume":"75","author":"DR Hill","year":"2006","unstructured":"Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402\u201315.","journal-title":"Am J Trop Med Hyg"},{"key":"2555_CR28","unstructured":"WHO. 2010. Guidelines for the treatment of malaria. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/44227\/1\/9789241547925_eng.pdf?ua=1\n                    \n                  ."},{"key":"2555_CR29","unstructured":"Sanofi-Aventis. 2017. Prescribing information for primaquine. \n                    http:\/\/products.sanofi.ca\/en\/primaquine.pdf\n                    \n                  . Accessed 27 Aug 2018."},{"key":"2555_CR30","first-page":"738","volume":"74","author":"MA Paul","year":"2003","unstructured":"Paul MA, McCarthy AE, Gibson N, Kenny G, Cook T, Gray G. The impact of primaquine and Malarone on psychomotor performance. Aviat Space Environ Med. 2003;74:738\u201345.","journal-title":"Aviat Space Environ Med"},{"key":"2555_CR31","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1086\/324085","volume":"33","author":"JK Baird","year":"2001","unstructured":"Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, et al. Randomized, parallel, placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001;33:1990\u20137.","journal-title":"Clin Infect Dis"},{"key":"2555_CR32","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/S0140-6736(95)92898-7","volume":"345","author":"DJ Fryauff","year":"1995","unstructured":"Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, et al. Randomized placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 1995;345:1190\u20133.","journal-title":"Lancet."},{"key":"2555_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12688\/wellcomeopenres.10658.1","volume":"2","author":"MA Bitta","year":"2017","unstructured":"Bitta MA, Kariuki SM, Mwita C, Gwyer S, Mwai L, Newton CRJC. Antimalarial drugs and the prevalence of mental and neurologic manifestations: a systematic review and meta-analysis. Wellcome Open Res. 2017;2:13.","journal-title":"Wellcome Open Res."},{"key":"2555_CR34","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jama.1952.72930340022010b","volume":"149","author":"CB Clayman","year":"1952","unstructured":"Clayman CB, Arnold J, Hockwald RS, Yount EH Jr, Edgcomb JH, Alving AS. Toxicity of primaquine in Caucasians. J Am Med Assoc. 1952;149:1563\u20138.","journal-title":"J Am Med Assoc"},{"key":"2555_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4269\/ajtmh.1949.s1-29.341","volume":"29","author":"A Loken","year":"1949","unstructured":"Loken A. Pamaquine\u00a0poisoning in man, with a clinicopathologic study of one case. Am J Trop Med Hyg. 1949;29:341\u201352.","journal-title":"Am J Trop Med Hyg"},{"key":"2555_CR36","unstructured":"CDC. Frequently Asked Questions \u2013 Malaria. \n                    https:\/\/www.cdc.gov\/malaria\/about\/faqs.html\n                    \n                  . Accessed 16 Mar 2018."},{"key":"2555_CR37","first-page":"147","volume":"9","author":"WK Blackie","year":"1935","unstructured":"Blackie WK. A fatal case of Plasmoquine poisoning. South Afr Med J. 1935;9:147\u20138.","journal-title":"South Afr Med J."},{"key":"2555_CR38","first-page":"143","volume":"32","author":"W Cordes","year":"1928","unstructured":"Cordes W. [Incidents in Plasmochin Treatment](in Gernan). Archiv f\u00fcr Schiffs-und Tropenhygiene. 1928;32:143\u20138.","journal-title":"Archiv f\u00fcr Schiffs-und Tropenhygiene."},{"key":"2555_CR39","first-page":"83","volume":"70","author":"W Schulemann","year":"1935","unstructured":"Schulemann W. The new synthetic drugs. Ind Med Gaz. 1935;70:83\u20138.","journal-title":"Ind Med Gaz."},{"key":"2555_CR40","first-page":"26","volume":"27","author":"AS Alving","year":"1948","unstructured":"Alving AS, Craige B Jr, Jones R Jr, Whorton CM, Pullman TN, Eichelberger L. Pentaquine (SN-13276), a therapeutic agent effective in reducing the relapse rate in vivax malaria. J Clin Invest. 1948;27:26\u201333.","journal-title":"J Clin Invest."},{"key":"2555_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1172\/JCI101955","volume":"27","author":"B Craige Jr","year":"1948","unstructured":"Craige B Jr, Eichelberger L, Jones R Jr, Alving AS, Pullman TN, Whorton MC. The toxicity of large doses of pentaquine (SN13276), a new antimalarial drug. J Clin Invest. 1948;27:17\u201324.","journal-title":"J Clin Invest."},{"key":"2555_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","volume":"58","author":"RP Brueckner","year":"1998","unstructured":"Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-human safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58:645\u20139.","journal-title":"Am J Trop Med Hyg."},{"key":"2555_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1128\/AAC.24.5.615","volume":"24","author":"LH Schmidt","year":"1983","unstructured":"Schmidt LH. Relationships between chemical structures of 8-aminoquinolines and their capacities for radical cure of infections with Plasmodium cynomolgi in rhesus monkeys. Antimicrob Agents Chemother. 1983;24:615\u201352.","journal-title":"Antimicrob Agents Chemother"},{"key":"2555_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1475-2875-10-212","volume":"10","author":"GS Dow","year":"2011","unstructured":"Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, et al. Radical curative efficacy of tafenoquine combinations regimens in P. cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011;10:212.","journal-title":"Malar J."},{"key":"2555_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.clinph.2011.07.046","volume":"123","author":"JJ Kavanagh","year":"2012","unstructured":"Kavanagh JJ, Grant GD, Anoopkumar-Dukie S. Low dosage promethazine and loratadine negatively affect neuromotor function. Clin Neurophysiol. 2012;123:780\u20136.","journal-title":"Clin Neurophysiol"},{"key":"2555_CR46","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.clinph.2014.03.026","volume":"125","author":"L Baumann-Birkbeck","year":"2014","unstructured":"Baumann-Birkbeck L, Grant GD, Anoopkumar-Dukie S, Kavanagh JJ. Drowsiness and motor responses to consecutive daily doses of promethazine and loratadine. Clin Neurophysiol. 2014;125:2390\u20136.","journal-title":"Clin Neurophysiol"},{"key":"2555_CR47","volume-title":"Medical Aspects of Harsh Environments","author":"AJ Benson","year":"2002","unstructured":"Benson AJ. Chapter 35: Motion Sickness. In: Lounsbury DE, editor. Medical Aspects of Harsh Environments, vol. 2. Falls Church: Office of the Surgeon General, Department of the Army; 2002."},{"key":"2555_CR48","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1128\/AAC.00354-09","volume":"54","author":"PE Nasveld","year":"2010","unstructured":"Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in non-immune subjects. Antimicrob Agents Chemother. 2010;54:792\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2555_CR49","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1086\/324081","volume":"33","author":"GD Shanks","year":"2001","unstructured":"Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33:1968\u201374.","journal-title":"Clin Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-018-2555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-018-2555-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-018-2555-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:04:45Z","timestamp":1572998685000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-018-2555-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1186\/s12936-018-2555-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"22 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"407"}}